This case was targeting MBA students in M&A or the derivatives courses. In January 2011, Sanofi-Aventis was completing its offer conditions for acquiring Genzyme. The M&A valuation disputes were about the marketplace potential of alemtuzumab, a drug in Genzyme's pipeline, and how fast Genzyme could resolve some of its making problems.
To bridge the gap in their own estimates, advisers had suggested an up-front cash payment along with a contingent value right (CVR). Was a CVR the charming alternative to bridging the valuation difference?
The Sanofi-Aventis Acquisition of Genzyme Contingent Value Rights Case Study Solution
PUBLICATION DATE: October 22, 2014 PRODUCT #: UV6870-HCB-ENG
This is just an excerpt. This case is about FINANCE & ACCOUNTING
